Baidu
map

DCR:抗肿瘤坏死因子会增加UC手术患者术后储袋炎的可能

2020-01-29 不详 MedSci原创

在溃疡性结肠炎患者中,储袋炎是IPAA之后最常见的并发症。抗生素是治疗的主要手段,这表明营养不良在这种疾病的发病机理中起着至关重要的作用。抗肿瘤坏死因子药物已被证明会对肠道微生物组和局部宿主免疫产生不利影响。因此,这项研究的目的是评估溃疡性结肠炎患者事先接触生物制剂对储袋炎的影响。

背景:
溃疡性结肠炎患者中,储袋炎是IPAA之后最常见的并发症。抗生素是治疗的主要手段,这表明营养不良在这种疾病的发病机理中起着至关重要的作用。抗肿瘤坏死因子药物已被证明会对肠道微生物组和局部宿主免疫产生不利影响。因此,这项研究的目的是评估溃疡性结肠炎患者事先接触生物制剂对储袋炎的影响。

方法:
这是一项回顾性病例对照研究。研究人员对2000年至2010年间接受了恢复性直肠结肠镜切除术的溃疡性结肠炎患者进行了回顾性分析。主要观察指标:储袋炎的发生率。

结果:
本项研究纳入接受IPAA治疗的471例溃疡性结肠炎患者。储袋炎的发生率为40.4%。发生储袋炎的患者与未发生储袋炎的患者相比,患者的人口统计学特征,疾病特异性因素,手术方法和短期术后并发症没有差异。暴露于抗肿瘤坏死因子药物或术前使用类固醇的患者发生储袋炎的可能性更高(47.9% VS 36.5%,p = 0.027;类固醇:41.7%vs 23.3%,p = 0.048)。然而,在多变量分析中,只有抗肿瘤坏死因子疗法是治疗癌症的独立预测因子。

结论:
在接受IPAA治疗的溃疡性结肠炎患者中,抗肿瘤坏死因子暴露是发生储袋炎的唯一独立危险因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1362972, encodeId=948613629e285, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485483, encodeId=0cf21485483c9, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559813, encodeId=cb3f155981359, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565822, encodeId=48de1565822dd, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378664, encodeId=f8e83e8664d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:11:23 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-01-31 millore
  2. [GetPortalCommentsPageByObjectIdResponse(id=1362972, encodeId=948613629e285, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485483, encodeId=0cf21485483c9, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559813, encodeId=cb3f155981359, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565822, encodeId=48de1565822dd, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378664, encodeId=f8e83e8664d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:11:23 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1362972, encodeId=948613629e285, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485483, encodeId=0cf21485483c9, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559813, encodeId=cb3f155981359, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565822, encodeId=48de1565822dd, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378664, encodeId=f8e83e8664d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:11:23 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1362972, encodeId=948613629e285, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485483, encodeId=0cf21485483c9, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559813, encodeId=cb3f155981359, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565822, encodeId=48de1565822dd, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378664, encodeId=f8e83e8664d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:11:23 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1362972, encodeId=948613629e285, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485483, encodeId=0cf21485483c9, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559813, encodeId=cb3f155981359, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565822, encodeId=48de1565822dd, content=<a href='/topic/show?id=61785564089' target=_blank style='color:#2F92EE;'>#抗肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55640, encryptionId=61785564089, topicName=抗肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7415021136, createdName=zblhy, createdTime=Fri Jan 31 11:20:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378664, encodeId=f8e83e8664d0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:11:23 CST 2020, time=2020-01-30, status=1, ipAttribution=)]
    2020-01-30 1478fa69m73暂无昵称

    学习了

    0

相关资讯

IBD:轻-中度溃疡性结肠炎中使用激素和生物制剂的注意事项

皮质类固醇相关的不良事件的发生风险可能会限制全身激素的使用。口服或者是局部使用第二代皮质类固醇和生物治疗是目前IBD有效的治疗方法。本篇文章进行了皮质类固醇和生物制剂对于溃疡性结肠炎的安全性和耐受性的分析。

IBD:影响患有艰难梭菌感染的炎性肠病患者手术风险的增加因素分析

炎症性肠病(IBD)是艰难梭菌感染(CDI)的独立危险因素,CDI通常会导致IBD病情恶化。因此本项研究的目的是旨在评估与CDI的IBD不良结果相关的因素。

JCC : 抗肿瘤坏死因子在影响炎性肠病患者潜在发生结核感染的前瞻性研究

生物疗法彻底改变了免疫介导疾病的治疗方法,特别是炎症性肠病[IBD]和风湿病。然而,生物治疗与潜伏性结核再激活的风险增加有关。生物治疗期间定期监测潜伏性结核感染[LTBI]的重要性目前还没有得到应有的重视。

Baidu
map
Baidu
map
Baidu
map